IL104620A - Humanized monoclonal antibodies against human interleukin-5 - Google Patents

Humanized monoclonal antibodies against human interleukin-5

Info

Publication number
IL104620A
IL104620A IL10462093A IL10462093A IL104620A IL 104620 A IL104620 A IL 104620A IL 10462093 A IL10462093 A IL 10462093A IL 10462093 A IL10462093 A IL 10462093A IL 104620 A IL104620 A IL 104620A
Authority
IL
Israel
Prior art keywords
monoclonal antibodies
antibodies against
against human
humanized monoclonal
human interleukin
Prior art date
Application number
IL10462093A
Other languages
English (en)
Other versions
IL104620A0 (en
Original Assignee
Schering Plough Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Corp filed Critical Schering Plough Corp
Publication of IL104620A0 publication Critical patent/IL104620A0/xx
Publication of IL104620A publication Critical patent/IL104620A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL10462093A 1992-02-06 1993-02-04 Humanized monoclonal antibodies against human interleukin-5 IL104620A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83284292A 1992-02-06 1992-02-06

Publications (2)

Publication Number Publication Date
IL104620A0 IL104620A0 (en) 1993-06-10
IL104620A true IL104620A (en) 2000-02-29

Family

ID=25262763

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10462093A IL104620A (en) 1992-02-06 1993-02-04 Humanized monoclonal antibodies against human interleukin-5

Country Status (21)

Country Link
US (1) US6451982B1 (OSRAM)
EP (1) EP0625201A1 (OSRAM)
JP (2) JPH07505767A (OSRAM)
KR (2) KR0150060B1 (OSRAM)
CN (1) CN1077991A (OSRAM)
AR (1) AR248044A1 (OSRAM)
AU (1) AU683836B2 (OSRAM)
CA (1) CA2129445A1 (OSRAM)
CZ (1) CZ291039B6 (OSRAM)
FI (1) FI943635A0 (OSRAM)
HU (1) HUT67943A (OSRAM)
IL (1) IL104620A (OSRAM)
NO (1) NO942912L (OSRAM)
NZ (1) NZ249633A (OSRAM)
PL (1) PL176393B1 (OSRAM)
RU (1) RU94045919A (OSRAM)
SG (1) SG49597A1 (OSRAM)
SK (1) SK280610B6 (OSRAM)
TN (1) TNSN93012A1 (OSRAM)
WO (1) WO1993016184A1 (OSRAM)
ZA (1) ZA93779B (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104620A (en) 1992-02-06 2000-02-29 Schering Plough Corp Humanized monoclonal antibodies against human interleukin-5
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
DK0800536T3 (da) * 1994-12-23 2007-04-02 Smithkline Beecham Corp Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
EP0811691B1 (en) 1995-09-11 2004-12-01 Kyowa Hakko Kogyo Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
CA2479927C (en) * 2002-03-29 2013-03-12 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
US7927840B2 (en) * 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
ES2890882T3 (es) * 2002-10-16 2022-01-24 Gen Probe Inc Composiciones y procedimientos para detectar el virus del Nilo occidental
AU2003298187B2 (en) 2002-12-17 2010-09-16 Merck Patent Gmbh Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
JP4954709B2 (ja) 2004-10-28 2012-06-20 協和発酵キリン株式会社 子宮内膜症治療剤
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
MX2007011064A (es) 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
JP2010526087A (ja) 2007-04-30 2010-07-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗ｉｌ−５抗体を投与するための方法
ES2441945T3 (es) 2008-03-28 2014-02-07 Glaxosmithkline Llc Métodos de tratamiento
AU2009306708A1 (en) * 2008-10-23 2010-04-29 F. Hoffmann-La Roche Ag Determination of immunoglobulin encoding nucleid acid
EP2654790B1 (en) * 2010-12-22 2019-02-06 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
EP2791171A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
US9677018B2 (en) 2013-01-09 2017-06-13 Thyssenkrupp Industrial Solutions Ag Process for the production of synthesis gas from hard coal
SI3191513T1 (sl) 2014-09-08 2020-12-31 Cephalon, Inc. Uporaba reslizumaba za zdravljenje zmerne do hude eozinofilne astme
PE20181176A1 (es) 2015-08-24 2018-07-20 Glaxosmithkline Ip No 2 Ltd Composiciones biofarmaceuticas
CN110913887A (zh) 2017-06-06 2020-03-24 葛兰素史克有限责任公司 用于儿科患者的生物药物组合物和方法
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
US11224653B2 (en) 2017-08-24 2022-01-18 Cephalon, Inc. Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
TWI801425B (zh) * 2017-09-29 2023-05-11 大陸商江蘇恆瑞醫藥股份有限公司 Il-5 抗體、其抗原結合片段及醫藥用途
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
IL92180A (en) * 1988-11-03 1997-04-15 Schering Corp Pharmaceutical composition for preventing or reducing eosinophilia
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2041271A1 (en) * 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
IL104620A (en) 1992-02-06 2000-02-29 Schering Plough Corp Humanized monoclonal antibodies against human interleukin-5

Also Published As

Publication number Publication date
NZ249633A (en) 1995-12-21
PL176393B1 (pl) 1999-05-31
WO1993016184A1 (en) 1993-08-19
SG49597A1 (en) 1998-06-15
FI943635A7 (fi) 1994-08-05
FI943635L (fi) 1994-08-05
SK280610B6 (sk) 2000-05-16
FI943635A0 (fi) 1994-08-05
AU683836B2 (en) 1997-11-27
CZ291039B6 (cs) 2002-12-11
IL104620A0 (en) 1993-06-10
JPH07505767A (ja) 1995-06-29
HU9402293D0 (en) 1994-10-28
HUT67943A (en) 1995-05-29
SK91894A3 (en) 1995-02-08
US6451982B1 (en) 2002-09-17
JP2000210097A (ja) 2000-08-02
CZ191094A3 (en) 1994-12-15
NO942912L (no) 1994-10-06
AU3656093A (en) 1993-09-03
EP0625201A1 (en) 1994-11-23
CN1077991A (zh) 1993-11-03
RU94045919A (ru) 1996-11-10
ZA93779B (en) 1993-08-05
AR248044A1 (es) 1995-05-31
KR0150060B1 (ko) 1998-08-17
TNSN93012A1 (fr) 1994-03-17
KR950700413A (ko) 1995-01-16
CA2129445A1 (en) 1993-08-07
NO942912D0 (OSRAM) 1994-08-05

Similar Documents

Publication Publication Date Title
IL104620A (en) Humanized monoclonal antibodies against human interleukin-5
AU1289795A (en) Monoclonal antibodies specific for human interleukin-5
PL309249A1 (en) Humanised antibodies against l-selectin
ZA949341B (en) Humanized antibodies and uses thereof
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
IL108199A0 (en) Monoclonal antibodies against the human il-4 receptor and hybridomas producing the same
EP0823941A4 (en) HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP0578515A3 (en) Humanized monoclonal antibodies.
EP0580859A4 (en) Anti-eda monoclonal antibody
GB8910395D0 (en) Human monoclonal antibody and hybridoma producing the same
EP0683675A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST CYTOMEGALOVIRUS.
EP0506523A3 (en) Monoclonal antibodies
EP0498767A3 (en) Chimeric antiidiotypic monoclonal antibodies
IL102088A0 (en) Me20:monoclonal antibodies and antigen for human melanoma
EP0508282A3 (en) Anti-idiotypic monoclonal antibodies
ZA951113B (en) Tumor assosiated monoclonal antibody 123av16
EP0546634A3 (en) Tumor associated monoclonal antibody 88bv59
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
GB9212074D0 (en) Monoclonal antibody
SG64332A1 (en) Monoclonal antibody
AU5852094A (en) Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
IE900593L (en) Monoclonal antibodies
IE900922L (en) Monoclonal antibody
IE901210L (en) Monoclonal antibody
GB9118013D0 (en) Monoclonal antibodies and their use

Legal Events

Date Code Title Description
FF Patent granted
RH1 Patent not in force